Compare · DXCM vs SI
DXCM vs SI
Side-by-side comparison of DexCom Inc. (DXCM) and Shoulder Innovations Inc. (SI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 94.9x SI ($296.1M).
- Over the past year, DXCM is down 10.0% and SI is down 5.9% - SI leads by 4.1 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 1 for SI).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Shoulder Innovations Inc.
- Price
- $77.05+5.77%
- $14.20-1.53%
- Market cap
- $28.11B
- $296.1M
- 1M return
- +26.45%
- +10.16%
- 1Y return
- -10.04%
- -5.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2025
- News (4w)
- 26
- 1
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Shoulder Innovations Inc.
Silvergate Capital Corporation operates as a bank holding company for Silvergate Bank that provides banking products and services to business and individual clients in the United States and internationally. The company accepts deposit products, including interest and noninterest bearing demand accounts, money market and savings accounts, and certificates of deposit accounts. Its loan products comprise one-to-four family real estate loans, multi-family real estate loans, commercial real estate loans, construction loans, commercial and industrial loans, mortgage warehouse loans, and reverse mortgage loans, as well as consumer loans and other loans secured by personal property. The company also provides cash management services for digital currency-related businesses. The company was founded in 1988 and is headquartered in La Jolla, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest SI
- Shoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form 10-Q filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
- CEO & Executive Chairman Ball Robert Joseph exercised 10,000 shares at a strike of $2.48, increasing direct ownership by 3% to 300,018 units (SEC Form 4)
- SEC Form DEF 14A filed by Shoulder Innovations Inc.
- SEC Form DEFA14A filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Shoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem
- Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026